Eine 80-jährige Alzheimer-Patientin zeigte nach der Einnahme von Psilocybin, dem Wirkstoff von Zauberpilzen, eine bemerkenswerte Verbesserung ihrer Symptome. Die Forscher vermuten, dass die Substanz die Neuroplastizität im Gehirn fördert und kognitive Funktionen wiederherstellt.
Australia is manufacturing MDMA and psilocybin for therapeutic use, with companies like Breathe Life Sciences producing these drugs for patients with PTSD and treatment-resistant depression. While early results are promising, experts urge caution due to costs and potential side effects.
Australia is pioneering psychedelic medicine, with licensed facilities manufacturing MDMA for PTSD and psilocybin for depression. Patients like Jess Yugovich report life-changing therapeutic benefits, though experts caution about costs and suitability, emphasizing the distinction between regulated medical use and illicit street drugs.
A new clinical trial suggests a single dose of psilocybin may effectively treat cocaine addiction, with participants showing higher abstinence rates than those receiving a placebo. The study, notable for its majority Black participant group, highlights psilocybin's potential as a catalyst in therapeutic processes for addiction.
Participants took 25mg of psilocybin, reporting deeper psychological insight and better wellbeing a month laterA single dose of psilocybin, the active ingredient in magic mushrooms, can induce anatomical changes in the brain, according to research among people who took the psychedelic compound for the first time.Scientists spotted apparent changes in the brain’s structure which were still apparent a month after healthy volunteers took the drug. If confirmed, they may help explain the therapeutic effects that psychedelics can have on anxiety, depression and addiction, researchers said. Continue reading...
President Donald Trump signed an executive order on Saturday aimed at accelerating psychedelics research, directing agencies to expand clinical trials and Right to Try access for psilocybin, MDMA and ibogaine. The order leaves drug scheduling unchanged and comes amid stalled cannabis rescheduling efforts, raising questions about whether psychedelics will face similar federal delays. Psychedelic stocks rallied significantly following the announcement, with AtaiBeckley jumping roughly 25%.
Trump signed an executive order Saturday to ease research restrictions on psychedelic drugs like psilocybin and LSD, aiming to accelerate studies into their potential for treating mental health conditions.
